Trial Profile
A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms DARWIN3
- Sponsors Galapagos NV; Gilead Sciences
- 15 Nov 2023 Results of pooled analysis from DARWIN 1-3 (NCT01888874, NCT01894516, NCT02065700) and FINCH 1-4 (NCT02889796, NCT02873936, NCT02886728, NCT03025308) trials assessing the incidence of malignancies excluding nonmelanoma skin cancer (NMSC), NMSC, MACE and venous thromboembolism (VTE) in patients treated with FIL200 or FIL100, presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis from 7 clinical trials NCT01888874, NCT01894516 NCT02889796, NCT02873936, NCT02886728, NCT02065700 & NCT03025308, presented at the ACR Convergence 2023.
- 15 Nov 2023 Results providing an update on the safety and efficacy of FIL 200 mg (FIL200) in patients with RA, with or without MTX, with a maximum of 8.2 years of exposure presented at the ACR Convergence 2023